solid end strong
prospect maintain buy
street estim bracket guidanc
report solid end year ep arriv top end
guidanc rang visibl remain solid segment end
ntm backlog coverag rais estim in-lin coverag
recogn prior year expect pace growth ta
par importantli continu expect opex leverag support
ep growth mid-teen outpac revenu growth
aggress share repurchas could provid addit upsid ep growth
strong visibl within note previous think setup
 segment revenu attract report
ntm backlog y/i notabl appear gain traction
smart trial offer whose associ book approach
quarter revenu estim
impli backlog coverag in-lin backlog
coverag year prior would note revis estim also
contempl expect coronavirus-rel impact
separ signal nois much earn call spent
traction within oce offer recent win top
pharma client noteworthi prospect deploy
potenti seat onto platform expect develop
materi alter near term fundament busi assum at-scal
per seat price per year seat would worth
annual revenu ta revenu base layer top
expect multi-year contract roll-out live
expect see notabl mix shift revenu outsid year target
like near term oce-rel catalyst stock see would
addit win larg pharma could drive upsid
valuat multipl demonstr sustain capac gain market share
ep estim crimp think remain posit
upsid rais revenu estim increas
confid somewhat off-set fx headwind smaller
extent impat coronaviru lower estim
reflect conserv ta revenu acceler assumpt
lower base ep
model contempl share repurchas spread
year repurchas aggress deploy greater
amount could expect see upsid ep estim els equal
fx headwind slower acceler organ
align backlog coverag off-set
fx corona-rel drag
expect slower organ growth mute
fx drag
fx drag slower pace opex leverag
tr target
pt pt impli price-to-earnings multipl ep estim
page
page
share upsid current strh factsetstrh pt low/high rangesourc factset strh research ia hold inc
page
sandi draper statement dollar y/i total gross depreci restructur merger related- impair oper fit incl restruc net interest expens incom incom incom tax tax equiti unconsolid equiti earn unconsolid net net loss incom attribut non-controlling net incom attribut dilut dilut share forma adjust net adj pre-tax tax non-gaap net non-gaap growth forma adjust ebitdaadjust margin robinson humphrey research estimatestick iqva
iqvia largest cro revenu oper countri employe
compani found headquart durham nc compani formerli quintil
merg im health combin entiti iqvia oper three segment commerci
solut data technolog drive real world evid use life scienc client clinic
trial integr healthcar servic contract sale compris
respect sale iqvia first went public taken privat privat equiti
went public
buy rate base view ebitda growth exceed revenu growth due
oper leverag cost synergi recognit expect manag reinforc oper
perform share repurchas expect contribut mid-teen ep growth
valuat risk
pt assign probabl low case price-to-earnings stock mid case
high case pt impli price-to-earnings multipl
ep estim approxim peer averag ntm multipl justifi view given
peer lead book perform anticip acceler revenu growth one leader
ep growth well view investor begin compar mid/larg
cap high visibl growth compani typic trade pe low- mid-
risk rate price target
unexpect cancel late stage busi net book bill trend deterior
leverag start increas
sandi draper herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
